Pediatric rheumatology for the adult rheumatologist II

Uveitis in juvenile idiopathic arthritis

Tracey Wright, Randy Q. Cron

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Uveitis is an important and frequent extra-articular manifestation of juvenile idiopathic arthritis (JIA) that may result in poor visual outcome. Without early detection and aggressive therapy, the uveitis and topical steroid therapy used to treat it may result in cataracts, glaucoma, and even blindness. Fortunately, a variety of systemically administered anti-inflammatory agents have been found useful for the treatment of JIA associated uveitis. Methotrexate is often the first line disease modifying systemic agent used to help wean topical corticosteroids, but when this is not sufficiently effective there are a variety of other systemic medicines available. In particular, one of the tumor necrosis factor-α inhibitors, infliximab, has shown some promising results in difficult to treat JIA associated uveitis. With early screening and detection combined with aggressive therapy in difficult to treat cases, the morbidity associated with uveitis as part of JIA is on the decline.

Original languageEnglish (US)
Pages (from-to)205-210
Number of pages6
JournalJournal of Clinical Rheumatology
Volume13
Issue number4
DOIs
StatePublished - Aug 2007

Fingerprint

Juvenile Arthritis
Uveitis
Rheumatology
Pediatrics
Blindness
Therapeutics
Methotrexate
Glaucoma
Cataract
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Joints
Steroids
Rheumatologists
Morbidity

ASJC Scopus subject areas

  • Rheumatology

Cite this

Pediatric rheumatology for the adult rheumatologist II : Uveitis in juvenile idiopathic arthritis. / Wright, Tracey; Cron, Randy Q.

In: Journal of Clinical Rheumatology, Vol. 13, No. 4, 08.2007, p. 205-210.

Research output: Contribution to journalArticle

@article{b26d2d3aaf4b45f3aabb84af36ffe457,
title = "Pediatric rheumatology for the adult rheumatologist II: Uveitis in juvenile idiopathic arthritis",
abstract = "Uveitis is an important and frequent extra-articular manifestation of juvenile idiopathic arthritis (JIA) that may result in poor visual outcome. Without early detection and aggressive therapy, the uveitis and topical steroid therapy used to treat it may result in cataracts, glaucoma, and even blindness. Fortunately, a variety of systemically administered anti-inflammatory agents have been found useful for the treatment of JIA associated uveitis. Methotrexate is often the first line disease modifying systemic agent used to help wean topical corticosteroids, but when this is not sufficiently effective there are a variety of other systemic medicines available. In particular, one of the tumor necrosis factor-α inhibitors, infliximab, has shown some promising results in difficult to treat JIA associated uveitis. With early screening and detection combined with aggressive therapy in difficult to treat cases, the morbidity associated with uveitis as part of JIA is on the decline.",
author = "Tracey Wright and Cron, {Randy Q.}",
year = "2007",
month = "8",
doi = "10.1097/RHU.0b013e31813c0e36",
language = "English (US)",
volume = "13",
pages = "205--210",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Pediatric rheumatology for the adult rheumatologist II

T2 - Uveitis in juvenile idiopathic arthritis

AU - Wright, Tracey

AU - Cron, Randy Q.

PY - 2007/8

Y1 - 2007/8

N2 - Uveitis is an important and frequent extra-articular manifestation of juvenile idiopathic arthritis (JIA) that may result in poor visual outcome. Without early detection and aggressive therapy, the uveitis and topical steroid therapy used to treat it may result in cataracts, glaucoma, and even blindness. Fortunately, a variety of systemically administered anti-inflammatory agents have been found useful for the treatment of JIA associated uveitis. Methotrexate is often the first line disease modifying systemic agent used to help wean topical corticosteroids, but when this is not sufficiently effective there are a variety of other systemic medicines available. In particular, one of the tumor necrosis factor-α inhibitors, infliximab, has shown some promising results in difficult to treat JIA associated uveitis. With early screening and detection combined with aggressive therapy in difficult to treat cases, the morbidity associated with uveitis as part of JIA is on the decline.

AB - Uveitis is an important and frequent extra-articular manifestation of juvenile idiopathic arthritis (JIA) that may result in poor visual outcome. Without early detection and aggressive therapy, the uveitis and topical steroid therapy used to treat it may result in cataracts, glaucoma, and even blindness. Fortunately, a variety of systemically administered anti-inflammatory agents have been found useful for the treatment of JIA associated uveitis. Methotrexate is often the first line disease modifying systemic agent used to help wean topical corticosteroids, but when this is not sufficiently effective there are a variety of other systemic medicines available. In particular, one of the tumor necrosis factor-α inhibitors, infliximab, has shown some promising results in difficult to treat JIA associated uveitis. With early screening and detection combined with aggressive therapy in difficult to treat cases, the morbidity associated with uveitis as part of JIA is on the decline.

UR - http://www.scopus.com/inward/record.url?scp=34548439843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548439843&partnerID=8YFLogxK

U2 - 10.1097/RHU.0b013e31813c0e36

DO - 10.1097/RHU.0b013e31813c0e36

M3 - Article

VL - 13

SP - 205

EP - 210

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 4

ER -